CXCL10 and melanoma: On the other hand, there were no significant relationships between serum levels of CXCL10 (Figure 2A) and CCL22 (Figure 3A) and the objective response to nivolumab in patients with advanced melanoma (CXCL10: p = 0.674, CCL22: p = 0.360).